Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
The Latest Advances and Challenges in Viral Hepatitis
share announcement

The Latest Advances and Challenges in Viral Hepatitis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Infectious Diseases".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1131

Special Issue Editors

Prof. Dr. Adriana Vince

E-Mail Website
Guest Editor
Department for Viral Hepatitis, University Hospital for Infectious Diseases, Zagreb, Croati
Interests: viral hepatitis; non-alcoholic fatty liver disease; infectious diseases; human papilloma viruses; COVID-19
Prof. Dr. Robert Flisiak

E-Mail Website
Guest Editor
Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
Interests: infectious diseases; viral hepatitis; liver; COVID-19
Special Issues, Collections and Topics in MDPI journals
Dr. Snjezana Zidovec Lepej

E-Mail Website
Guest Editor
Department of Immunological and Molecular Diagnostics, University Hospital for Infectious Diseases, Zagreb, Croatia
Interests: viral hepatitis; hepatitis C; HIV; virology; immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Viral hepatitis is a field of medicine where we have faced enormous advances in the last ten years. Antiviral therapy for hepatitis C and wide implementation of the HBV vaccine in infants are promising a new era without chronic hepatitis in the nearest future. Yet there are challenges remaining; insufficient screening and linkage to care in many countries that are still leaving untreated patients to develop cirrhosis and hepatocellular carcinoma, since patients treated during the advanced fibrosis stages can develop HCC as well. In some risk populations, HCV reinfection is occurring, and we still do not have a cure for hepatitis B. In this Special Issue, we would like to emphasize the importance of recent advances in the field but also address each of the remaining challenges, as well as state-of-the art research strategies.

Prof. Dr. Adriana Vince
Prof. Dr. Robert Flisiak
Dr. Snjezana Zidovec Lepej
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatitis B virus
  • hepatitis C virus
  • antiviral treatment
  • hepatocellular carcinoma
  • biomarkers
  • screening

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2235 KiB  
Article
The Impact of Liver Steatosis on Interleukin and Growth Factors Kinetics during Chronic Hepatitis C Treatment
by Leona Radmanic Matotek, Snjezana Zidovec-Lepej, Nikolina Salek, Adriana Vince and Neven Papic
J. Clin. Med. 2024, 13(16), 4849; https://doi.org/10.3390/jcm13164849 - 16 Aug 2024
Viewed by 762
Abstract
Background/Objectives: Various biological response modifiers play important roles in the immunopathogenesis of chronic hepatitis C (CHC). While serum levels of cytokines and growth factors change with the disease severity and treatment responses, the impact of concomitant liver steatosis on systemic inflammatory response is [...] Read more.
Background/Objectives: Various biological response modifiers play important roles in the immunopathogenesis of chronic hepatitis C (CHC). While serum levels of cytokines and growth factors change with the disease severity and treatment responses, the impact of concomitant liver steatosis on systemic inflammatory response is largely unknown. The aim of this study was to analyze the characteristics and kinetics of serum profiles of interleukins and growth factors in CHC patients with steatotic liver disease (SLD). Methods: Serum concentrations of 12 cytokines (IL-5, IL-13, IL-2, IL-6, IL-9, IL-10, IFN-γ, TNF-α, IL-17A, IL-17F, IL-4 and IL-22) and 6 growth factors (Angiopoietin-2, EGF, EPO, HGF, SCF, VEGF) were analyzed in 56 CHC patients at four time points (baseline, week 4, week 8 and SVR12) with bead-based flow cytometry assay. Results: At baseline, patients with SLD had significantly lower IL-9, IL-10, IL-13 and IL-22 and higher serum concentrations of EGF, VEGF and ANG. In a subgroup of patients with advanced liver fibrosis, SLD was linked with lower serum concentrations of IL-4, IL-5, IL-9, IL-10, IL-13 and IL-22 and higher concentrations of HGH and VEGF. Distinct cytokine kinetics during DAA treatment was observed, and SLD was identified as the main source of variation for IL-5, IL-9, IL-10, IL-13, IL-17A, IL-22, EGF, VEGF and ANG. Patients with SLD at SVR12 had significantly higher VEGF and HGF serum concentrations. Conclusions: SLD is associated with distinct cytokine and growth factor profiles and kinetics during CHC treatment, which might be associated with disease severity and the capacity for liver regeneration and contribute to fibrosis persistence. Full article
(This article belongs to the Special Issue The Latest Advances and Challenges in Viral Hepatitis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop